Adjusted risks associated with GD in the overall series, in patients without cirrhosis and without diabetes, at multivariate logistic regression analysis.

<p>Each variable adjusted for the others in the table.</p

Anthropometric, biochemical and clinical variables in patients with NAFLD with or without GD (univariate analysis).

<p>Mean ± SD or number of cases and (%).</p>+<p>P-values (ANOVA or chi-square test).</p>*<p>Variables that maintained significance when the subjects diagnosed with cirrhosis were excluded from analysis.</p

Percentage of necro inflammatory grading (left), fibrosis staging (middle) and steatosis (right) according to the presence or absence of GD.

<p>For necroinflammatory grade (IV  =  grade IV, V, VI and VII together). Analysis for trend: Necroinflammatory grade p = 0.01, Fibrosis stage p = 0.0001, Steatosis not significant (p = 0.7).</p

Baseline Demographic, Laboratory, Metabolic, and Histological Features of 366 Italian Patients with Non-alcoholic Fatty Liver Disease.

<p>Abbreviation: IU, international units; HOMA, homeostasis model assessment; HDL, high density lipoprotein. Data are given as mean ± standard deviation, or as number of cases (%).</p

Association of the GCKR rs780094 genotype and liver damage as evaluated by unadjusted and adjusted models in 366 Patients with Non-alcoholic Fatty Liver Disease.

<p>Unadjusted and adjusted OR were presented for PNPLA3 and GCKR SNPs, and only for clinical, metabolic and histological variables significant at univariate analysis.</p><p>PNPLA3 and GCKR SNPs, when not significant, were forced into the models.</p

Prevalence of significant fibrosis according to GCKR rs780094 SNP in the Sicilian cohort, in the Center/Northern Italian cohort, and in the combined cohorts of NAFLD patients.

<p>*p = 0.02 for prevalence of F2–F4 fibrosis according to GCKR genotype; ° p = 0.04 for prevalence of F2–F4 fibrosis according to GCKR genotype; ∧p = 0.001 for prevalence of F2–F4 fibrosis according to GCKR genotype.</p

Association of the rs780094 C→T GCKR SNP with anthropometric, biochemical, metabolic and histological features in 366 Patients with Non-alcoholic Fatty Liver Disease.

<p>Data are given as mean ± SD or as number of cases. HDL: high-density lipoprotein; HOMA: homeostasis model assessment.</p>°<p>by ANOVA;</p>*<p>p = 0.02 versus GCKR CC/CT.</p